Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study.
Clé DV, Atta EH, Dias DSP, Lima CBL, Bonduel M, Sciuccati G, Medeiros LA, de Oliveira MM, Blum Fonseca PB, Saad STO, Hamerschlak N, Salvino MA, Garanito MP, Pazin-Filho A, Scheinberg P, Calado RT. Clé DV, et al. Ann Hematol. 2018 Nov;97(11):2039-2046. doi: 10.1007/s00277-018-3416-4. Epub 2018 Jul 5. Ann Hematol. 2018. PMID: 29978284
Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia.
Clé DV, Atta EH, Dias DS, Lima CB, Bonduel M, Sciuccati G, Medeiros LA, de Oliveira MM, Salvino MA, Garanito M, Saad ST, Calado RT, Scheinberg P. Clé DV, et al. Haematologica. 2015 Sep;100(9):e345-7. doi: 10.3324/haematol.2015.123760. Epub 2015 Apr 10. Haematologica. 2015. PMID: 25862703 Free PMC article. Clinical Trial. No abstract available.
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients.
Clé DV, Hirayama AV, Alencar AJ, Costa LJ, Feliciano JVP, Mattos ER, Cordeiro AC, Salvino MA, Barros GMN, de Lima M, Scheinberg P, Guerino-Cunha RL. Clé DV, et al. Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S3-S12. doi: 10.1016/j.htct.2021.09.001. Hematol Transfus Cell Ther. 2021. PMID: 34794793 Free PMC article.
Pathogenic TERT promoter variants in telomere diseases.
Gutierrez-Rodrigues F, Donaires FS, Pinto A, Vicente A, Dillon LW, Clé DV, Santana BA, Pirooznia M, Ibanez MDPF, Townsley DM, Kajigaya S, Hourigan CS, Cooper JN, Calado RT, Young NS. Gutierrez-Rodrigues F, et al. Among authors: cle dv. Genet Med. 2019 Jul;21(7):1594-1602. doi: 10.1038/s41436-018-0385-x. Epub 2018 Dec 7. Genet Med. 2019. PMID: 30523342 Free PMC article.
Somatic genetic rescue in hematopoietic cells in GATA2 deficiency.
Catto LFB, Borges G, Pinto AL, Clé DV, Chahud F, Santana BA, Donaires FS, Calado RT. Catto LFB, et al. Among authors: cle dv. Blood. 2020 Aug 20;136(8):1002-1005. doi: 10.1182/blood.2020005538. Blood. 2020. PMID: 32556109 Free article. No abstract available.
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma.
Alencar AJ, Hirayama AV, Clé DV, Salvino MA, Perini G, Arrais C, Baiocchi O, Palma LC, Colturato I, Vaz J, Chiattone R, de Lima M, Filho JS, Nabhan S, Rocha V, Guerino-Cunha RL, Chiattone CS. Alencar AJ, et al. Among authors: cle dv. Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S22-S29. doi: 10.1016/j.htct.2021.09.003. Hematol Transfus Cell Ther. 2021. PMID: 34794792 Free PMC article.
19 results